Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MEN1 | O00255 | 4/20 | 0.36 |
| ▸ | KMT2A | Q03164 | 4/20 | 0.36 |
| ▸ | EED | O75530 | 1/20 | 0.34 |
| ▸ | RBBP4 | Q09028 | 1/20 | 0.34 |
| ▸ | SUZ12 | Q15022 | 1/20 | 0.34 |
| ▸ | EZH2 | Q15910 | 1/20 | 0.34 |
| ▸ | AEBP2 | Q6ZN18 | 1/20 | 0.34 |
| ▸ | PDE4D | Q08499 | 3/20 | 0.34 |
| ▸ | PDE4A | P27815 | 2/20 | 0.34 |
| ▸ | PDE4B | Q07343 | 2/20 | 0.34 |
| ▸ | PDE4C | Q08493 | 2/20 | 0.34 |
| ▸ | GPR119 | Q8TDV5 | 9/20 | 0.33 |
| ▸ | EPHX2 | P34913 | 1/20 | 0.33 |
| ▸ | MMP13 | P45452 | 1/20 | 0.33 |
| ▸ | NR1D1 | P20393 | 1/20 | 0.32 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2624345 | 0.86 | MEN1 (0.41) | MEN1KMT2AEEDRBBP4SUZ12 | |
| SCHEMBL2107370 | 0.81 | MEN1 (0.38) | MEN1KMT2AEEDRBBP4SUZ12 | |
| SCHEMBL2107369 | 0.81 | MEN1 (0.38) | MEN1KMT2AEEDRBBP4SUZ12 | |
| SCHEMBL14818384 | 0.79 | — | — | |
| SCHEMBL10247696 | 0.77 | — | — | |
| SCHEMBL10249867 | 0.75 | — | — | |
| SCHEMBL13758721 | 0.74 | KDM4E (0.32) | MEN1KMT2A | |
| SCHEMBL13758718 | 0.74 | — | — | |
| SCHEMBL10249698 | 0.74 | — | — | |
| SCHEMBL10249919 | 0.73 | — | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20120164103-A1 | Compounds and Methods for the Treatment or Prevention of Flavivirus Infections | VERTEX PHARMACEUTICALS (CANADA) INCORPORATED (CA) | 2012-06-28 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20120164103-A1 | Compounds and Methods for the Treatment or Prevention of Flavivirus Infections | ZC3HAV1, YBX1, HAX1 | MEN1 1088/4885KMT2A 3282/4885EED 2931/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.